• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利妥昔单抗为基础的化疗免疫治疗后淋巴瘤患者的迟发性 COVID-19 呼吸衰竭。

Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy.

机构信息

Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS.

Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Cancer Center, Kansas City, KS.

出版信息

Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e548-e550. doi: 10.1016/j.clml.2021.02.009. Epub 2021 Feb 27.

DOI:10.1016/j.clml.2021.02.009
PMID:33712408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7910130/
Abstract

• COVID-19 can present with delayed onset of symptoms in patients with lymphoma receiving rituximab-based chemoimmunotherapy. • Despite delayed onset of symptoms with prolonged asymptomatic period, outcomes can be particularly severe, including respiratory failure, thrombotic complications, and death.

摘要

• 接受基于利妥昔单抗的化疗免疫治疗的淋巴瘤患者 COVID-19 可出现症状延迟发作。 • 尽管症状延迟发作且无症状期延长，但结局可能特别严重，包括呼吸衰竭、血栓并发症和死亡。

相似文献

1
Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy.利妥昔单抗为基础的化疗免疫治疗后淋巴瘤患者的迟发性 COVID-19 呼吸衰竭。
Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):e548-e550. doi: 10.1016/j.clml.2021.02.009. Epub 2021 Feb 27.
2
DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.弥漫性大B细胞淋巴瘤在含利妥昔单抗的化疗过程中发展为致命性肝衰竭。
J Clin Exp Hematop. 2019;59(2):93-95. doi: 10.3960/jslrt.19004.
3
Composite diffuse large B-cell and peripheral T-cell lymphoma with T-helper phenotype treated with both rituximab and brentuximab vedotin.采用利妥昔单抗和维布妥昔单抗治疗的具有T辅助细胞表型的弥漫性大B细胞与外周T细胞复合淋巴瘤
Ann Hematol. 2021 Nov;100(11):2873-2875. doi: 10.1007/s00277-021-04633-6. Epub 2021 Aug 24.
4
Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?利妥昔单抗维持治疗弥漫性大B细胞淋巴瘤：XY是最重要的变量吗？
Haematologica. 2015 Jul;100(7):853-5. doi: 10.3324/haematol.2015.129924.
5
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab.来那度胺联合利妥昔单抗治疗老年复发弥漫性大B细胞淋巴瘤患者的长期无病生存
Haematologica. 2016 Sep;101(9):e385-6. doi: 10.3324/haematol.2016.147256. Epub 2016 May 31.
6
Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.一名弥漫性大B细胞淋巴瘤患者在接受含利妥昔单抗和粒细胞集落刺激因子的化疗免疫治疗期间发生广泛的机化性肺炎：病例报告及文献复习
Leuk Lymphoma. 2006 Aug;47(8):1683-5. doi: 10.1080/10428190600612586.
7
Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.接受血液透析的B细胞非霍奇金淋巴瘤患者含利妥昔单抗免疫化疗的耐受性和疗效
Leuk Lymphoma. 2016 Aug;57(8):1945-8. doi: 10.3109/10428194.2015.1115033. Epub 2015 Dec 21.
8
Curative potential of chemoimmunotherapy in diffuse large B cell lymphoma with hepatic and/or renal dysfunction.化疗免疫疗法对伴有肝和/或肾功能不全的弥漫性大B细胞淋巴瘤的治疗潜力。
Br J Haematol. 2019 Aug;186(4):e65-e67. doi: 10.1111/bjh.15897. Epub 2019 Mar 28.
9
Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.直接作用抗病毒药物与化疗免疫治疗联合用于 HCV 相关弥漫性大 B 细胞淋巴瘤。
Dig Liver Dis. 2019 May;51(5):719-723. doi: 10.1016/j.dld.2018.10.019. Epub 2018 Nov 3.
10
BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma.BEACOPP方案强化治疗联合利妥昔单抗用于治疗同时发生弥漫性大B细胞非霍奇金淋巴瘤的霍奇金淋巴瘤。
Leuk Lymphoma. 2013 Sep;54(9):2081-2. doi: 10.3109/10428194.2012.762514. Epub 2013 Feb 1.

引用本文的文献

1
Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study.奥滨尤妥珠单抗治疗与利妥昔单抗治疗的 COVID-19 患者结局比较：一项回顾性队列研究。
Virol J. 2024 Sep 9;21(1):212. doi: 10.1186/s12985-024-02484-x.
2
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy.对于淋巴系统恶性肿瘤患者，新型冠状病毒2型感染的管理是一项重大挑战：需要明确的治疗策略。
World J Virol. 2022 Jul 25;11(4):204-207. doi: 10.5501/wjv.v11.i4.204.
3
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review.淋巴瘤患者中的新型冠状病毒肺炎（严重急性呼吸综合征冠状病毒2感染）：综述
World J Virol. 2021 Nov 25;10(6):312-325. doi: 10.5501/wjv.v10.i6.312.
4
Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.接受抗 SARS-CoV-2 刺突蛋白单克隆抗体治疗的患者中出现 SARS-CoV-2 耐药突变：一例病例报告。
BMC Infect Dis. 2021 Dec 7;21(1):1223. doi: 10.1186/s12879-021-06902-1.
5
Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.滤泡性淋巴瘤患者在接受利妥昔单抗维持治疗后一年持续的 COVID-19 肺炎缓解和免疫性血小板减少症的发生：一例长期感染病例的随访报告及文献复习
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e810-e816. doi: 10.1016/j.clml.2021.07.004. Epub 2021 Jul 18.